NIH’S DR. CARL DIEFFENBACH DISCUSSES HIV TREATMENT SCIENCE AT 2016 RYAN WHITE CONFERENCE
August 26, 2016 • By AIDS.gov
As the 2016 National Ryan White Conference on HIV Care and Treatmentwound down in Washington, DC, NIH’s Dr. Carl Dieffenbach and his colleague Anne Rancourt joined us for a conversation on Facebook Live about HIV treatment. They discussed what scientists now know about the benefits of HIV treatment and when people diagnosed with HIV should begin treatment.Dr. Dieffenbach and Ms. Rancourt also discussed how the Ryan White HIV/AIDS Program as well as some jurisdictions are making big strides in improving outcomes along the HIV care continuum, increasing the proportion of individuals living with HIV who are in care, on treatment, and with a suppressed viral load. They also highlighted some ongoing NIH-supported research on HIV treatment. These include studies aimed at developing long-acting formulations of antiretroviral therapy (ART). In addition, NIH is supporting studies that address comorbidities that people living with HIV are experiencing as they live longer lives because of effective HIV treatment. One example is the REPREIVE Trial 
, which is studying how to prevent heart disease among people living with HIV.
, which is studying how to prevent heart disease among people living with HIV.View their conversation here . You can also view other videos and more coverage from the 2016 Ryan White Conference on AIDS.gov’s Facebook page .
. You can also view other videos and more coverage from the 2016 Ryan White Conference on AIDS.gov’s Facebook page .Related posts:
- HIV Vaccine Research: Update from NIH’s Dr. Dieffenbach from 2nd Day of AIDS 2016
- 2016 National Ryan White Conference on HIV Care and Treatment: Day One Recap
- NIH’s Dr. Dieffenbach Shares Final Update from AIDS 2016
- Dr. Carl Dieffenbach: IAS Conference Highlights HIV Treatment Advances – Day 4
- HRSA Calling for Abstracts for 2016 National Ryan White Conference on HIV Care & Treatment
No hay comentarios:
Publicar un comentario